SCHEMBL29762004

SCHEMBL29762004

Oc1cncc(-c2cccc(Cl)c2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.56
HSD17B1 P14061 2/20 0.51
ESR2 Q92731 1/20 0.47
TSHR P16473 1/20 0.47
IDO1 P14902 3/20 0.46
CYP11B1 P15538 2/20 0.45
CYP11B2 P19099 2/20 0.45
CYP3A4 P08684 2/20 0.44
CYP17A1 P05093 1/20 0.44
KDR P35968 1/20 0.43
XDH P47989 2/20 0.43
SLC22A12 Q96S37 2/20 0.43
CYP2C9 P11712 1/20 0.42
HSD17B2 P37059 1/20 0.42
MAP4K4 O95819 1/20 0.42
NPY5R Q15761 1/20 0.42
TET3 O43151 1/20 0.42
BBOX1 O75936 1/20 0.42
VEGFA P15692 1/20 0.42
FLT1 P17948 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16719102 1.00 ALOX5 (0.56) ALOX5HSD17B1ESR2TSHRIDO1
Formic Acid Methyl Ester SCHEMBL30432157 0.87 CYP11B1 (0.46) ALOX5HSD17B1ESR2IDO1CYP11B1
Formic Acid Methyl Ester SCHEMBL28432513 0.87 CYP11B1 (0.46) ALOX5HSD17B1ESR2IDO1CYP11B1
SCHEMBL30023892 0.84 ALOX5 (0.47) ALOX5HSD17B1ESR2TSHRIDO1
SCHEMBL29796762 0.84 IDO1 (0.52) ALOX5ESR2IDO1CYP11B1CYP11B2
SCHEMBL30345840 0.84 IDO1 (0.52) ALOX5ESR2IDO1CYP11B1CYP11B2
SCHEMBL30957059 0.84 IDO1 (0.52) ALOX5ESR2IDO1CYP11B1CYP11B2
SCHEMBL1029061 0.80 TSHR (0.73) ALOX5HSD17B1ESR2TSHRCYP3A4
SCHEMBL31226270 0.79 HSD17B1 (0.56) ALOX5HSD17B1CYP11B1CYP11B2CYP3A4
SCHEMBL1026676 0.78 HSD17B1 (0.55) ALOX5HSD17B1CYP11B1CYP11B2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12478615-B2 Prolyl hydroxylase inhibitors and methods of use AKEBIA THERAPEUTICS, INC. (US) 2025-11-25 US disclosed
US-20240358691-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE WARNER CHILCOTT COMPANY, LLC (PR) 2024-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358691-A1 PROLYL HYDROXYLASE INHIBITORS AND METHODS OF USE HIF1AN, EGLN3, EGLN2 ALOX5 400/4885HSD17B1 1206/4885ESR2 2224/4885
US-12478615-B2 Prolyl hydroxylase inhibitors and methods of use HIF1AN, EGLN3, HIF1A ALOX5 624/4885HSD17B1 862/4885ESR2 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.